Cilcare SAS · Small Molecule · Phase 1/2
ActiveTherapeuticStronger sources
Evidence
trial
Confidence
92%
Indications
Hearing LossSensorineural Hearing LossHidden Hearing LossCochlear Synaptopathy
Population
AdultDiabetesCochlear SynaptopathyHidden Hearing Loss


